A nomination committee has been established ahead of the 2025 annual general meeting in Redsense Medical AB (publ).

The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting May 8, 2024, consists of:

Johannes Köpple, appointed by ShapeQ GmbH

Susanne Olauson, appointed by Seventh Sense Adventures Holding AB

Oscar Bergman, appointed by Swedbank Robur Fonder

Susanne Olauson, the chairman of the board is convening

The nomination committee's task is to submit proposals to the annual general meeting regarding; nomination of the chairman at the meeting, number of board members, nomination of the chairman of the board and other members of the board, board fees and, where applicable, remuneration for committee work divided among each member, proposals for the election of auditors and auditors' fees and, to the extent deemed necessary, proposals for changes in current instruction for the Nomination committee.

Shareholders who wish to submit proposals to the nomination committee can do so via e-mail to info@redsensemedical.com no later than January 10, 2025.

The nomination committee's proposal will be presented in the notice to the 2025 annual general meeting and on the company's website; www.redsensemedical.com.

The annual general meeting will be held May 14, 2025, in Halmstad.

Contact information

For more information, please contact: 
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.